At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 47 enrolled
Drug / intervention
Brinzolamide 1% / timolol 0.5% Fixed Combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1% / timolol 0.5% Fixed Combination and Habitual prostaglandin monotherapy for Glaucoma and Ocular Hypertension. Completed, enrolled 47 participants.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartMar 2011
Primary CompletionApr 2013
TodayJul 2026
First PostedDec 20, 2010
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.5 years ago
Interventions
Brinzolamide 1% / timolol 0.5% Fixed Combinationdrug
Habitual prostaglandin monotherapydrug
Topical ocular therapy used daily as prescribed